These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9144890)

  • 21. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
    Small EJ; Vogelzang NJ
    J Clin Oncol; 1997 Jan; 15(1):382-8. PubMed ID: 8996165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
    Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
    Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
    Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
    Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Perhaps an explanation for the therapeutic escape of prostate cancer treated with antiandrogens].
    Jeanteur P
    Bull Cancer; 2000 Jul; 87(7-8):524-5. PubMed ID: 10969205
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.
    Leone G; Tucci M; Buttigliero C; Zichi C; Pignataro D; Bironzo P; Vignani F; Scagliotti GV; Di Maio M
    Endocr Relat Cancer; 2018 Jan; 25(1):R1-R9. PubMed ID: 28971898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
    Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
    J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antiandrogen withdrawal syndrome in relapsed prostate cancer.
    Scher HI; Kolvenbag GJ
    Eur Urol; 1997; 31 Suppl 2():3-7; discussion 24-7. PubMed ID: 9074903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
    El-Gabry EA; Strup SE; Gomella LG
    Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.
    Culig Z; Klocker H; Bartsch G; Hobisch A
    Am J Pharmacogenomics; 2001; 1(4):241-9. PubMed ID: 12083956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G; Kolvenbag G; Nash A
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
    Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiandrogen withdrawal syndrome with cyproterone acetate.
    Sella A; Flex D; Sulkes A; Baniel J
    Urology; 1998 Dec; 52(6):1091-3. PubMed ID: 9836560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.
    Miyamoto H; Marwah P; Marwah A; Lardy H; Chang C
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4440-4. PubMed ID: 12672951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
    Scher HI; Zhang ZF; Nanus D; Kelly WK
    Urology; 1996 Jan; 47(1A Suppl):61-9. PubMed ID: 8560680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.